Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen (SoraGVL)

St. Petersburg State Pavlov Medical University

Status and phase

Enrolling

Phase 2

Conditions

Myeloproliferative Neoplasm

Chronic Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse

Myelodysplastic Syndromes

Treatments

Drug: Sorafenib

Study type

Interventional

Funder types

Other

Identifiers

NCT06532084

19/24-n

Details and patient eligibility

About

This is a single-center randomized open-label phase II clinical trial to compare relapse prophylaxis with sorafenib and observation after graft-versus-host disease prophylaxis with post-transplantation bendamustine and cyclophosphamide in high-risk myeloid malignancies. This is an intention to treat study, where randomization is performed at first documentation of CR after engraftment.

Full description

Allogeneic hematopoietic stem cell transplantation (HCT) results steadily improve due to reduction of NRM. Standard risk patients now have the risk of HCT below 10% after matched donor transplantation. Nonetheless, there is limited improvement in CIR over time. Especially novel strategies to reduce relapse are needed for high-risk myeloid malignancies where standard HCT approaches result in relatively unfavorable outcomes. Among high-risk malignancies are refractory AML without hematological remission for HCT. In this group EFS rarely exceeds 15%. Some improvement in refractory AML was reported with intensified sequential conditioning regimens, but there use is limited to young and fit patients who comprise only around 20-30% of all refractory AML population. Also it was demonstrated that AML patients beyond CR2 have significantly worse prognosis than CR1 and CR2 patients. It is reported that long-term EFS in this group of patients is around 30%. The next adverse group of HCT recipients are patients with high-risk somatic mutations. It is reported in several studies that EFS in tp53-mutant AML even allografted in CR is 0%. Another adverse mutation is ASXL1, where also 0-10% EFS was demonstrated in large cohorts of patients. For therapy related myeloid malignancies it was also demonstrated that the CIR is higher and this group patients have even in CR have 30% EFS. Complex karyotype and monosomal karytope, involvement of chromosome 3 with EVI1 gene, which are common in this patients group, further exacerbate prognosis. Very high risk MDS was also reported to have dismal prognosis after allogeneic HCT. All these adverse groups were included in the study.

PTBCy GVHD prophylaxis provides augmented GVL and better disease control in high-risk myeloid malignancies, but GVL effect fades over time. While median relapse rate is significantly prolonged to 8 months against the previously reported in the literature 2-3 months, the relapse rate with long term follow up remains high. Thus this longer time to relapse gives enough time to initiate sorafenib prophylaxis which was shown to be one of the most promising agents for relapse prophylaxis. Given its immune modulatory properties the study hypothesis is that sorafenib with PTBCy GVHD prohylaxis will further augment GVL and facilitate better disease control.

Enrollment

88 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must undergo allogeneic hematopoietic stem cell transplantation with post-transplantation bendamustine AND cyclophosphamide from any donor.
Patients must have high-risk myeloid malignancy as an indication for transplantation defined as:
- acute myeloid leukemia not in hematological remission prior to transplantation,
- ≥ 3 remission of acute myeloid leukemia,
- any myeloid malignancy with bi-allelic tp53 mutation,
- any myeloid malignancy with complex karyotype,
- therapy-related myeloid malignancy not in MRD-negative response
- myelodysplastic syndrome with very high IPSS-R risk
- any myeloid malignancy with monosomal or t(3;3) karyotype,
- any myeloid malignancy with ASXL1, bi-allelic tp53 or RUNX1 mutation, EVI1 overexpression
- MDS/NPM unclassified not in hematologic remission.
Documented hematological remission in the bone marrow at the time of inclusion post-engraftment, measurable residual disease is allowed
First 100 days after allogeneic hematopoietic stem cell transplantation

Exclusion criteria

successfully treated relapse between transplantation and enrollment
use of any other planned method for prophylaxis of relapse besides sorafenib
donor lymphocyte infusion prior to randomization
Second malignancy not in complete remission within 6 months prior to randomization
Moderate or severe cardiac disease: ejection fraction <50%, unstable angina, stable angina NYHA class III or IV, chronic heart failure NYHA class III or IV, Lawn grade V arrhythmia, myocardial infarction within 3 months before inclusion
Stroke within 3 months of inclusion, unless related to the underlying malignancy
Severe decrease in pulmonary function: FEV1 <50% or DLCO<50% of predicted or respiratory distress or need for oxygen support;
Severe organ dysfunction: AST or ALT >10 upper normal limits, bilirubin >2 upper normal limits, creatinine >2 upper normal limits
Creatinine clearance < 30 mL/min
Uncontrolled bacterial or fungal infection at the time of enrollment defined by CRP> 70 mg/L
Requirement for vasopressor support at the time of enrollment
Requirement for positive-pressure oxygen at the time of enrollment
Karnofsky index <30%
Pregnancy
Somatic or psychiatric disorder making the patient unable to sign informed consent